四种高通量SARS-CoV-2抗体检测方法在相同患者样本中的性能特征差异
本研究利用残留血清样本,直接比较四种商用SARS-CoV-2抗体检测方法的性能。结果显示,在症状出现14天后的样本中,EUROIMMUN、Roche和Siemens的敏感性达93.1%至98.3%,优于DiaSorin的87.7%;Roche和Siemens的特异性均为100%,优于DiaSorin和EUROIMMUN。
要点
- 症状出现14天后,Roche和Siemens敏感性达98.3%和96.6%,特异性均100%。
- EUROIMMUN敏感性96.6%但特异性86.3%至96.4%,DiaSorin敏感性87.7%。
- Roche和Siemens检测适用于低流行区域,联合使用或可提升检测效能。
核心结论
- Roche和Siemens检测的敏感性和特异性可接受用于低流行区域,联合使用具有正交检测潜力。
研究设计与样本
- 基于SARS-CoV-2 RT-PCR检测、临床检验结果和采集日期识别残留血清样本,用四种商用检测方法分析。
主要发现
- RT-PCR阳性患者样本随时间推移阳性率增加;症状出现14天后,EUROIMMUN、Roche和Siemens敏感性分别为93.1%至96.6%、98.3%、96.6%,DiaSorin为87.7%。
- Roche和Siemens特异性均为100%,DiaSorin为96.1%至97.0%,EUROIMMUN为86.3%至96.4%。
关键数值与推荐
- EUROIMMUN敏感性93.1%至96.6%,Roche 98.3%,Siemens 96.6%,DiaSorin 87.7%(症状出现14天后)。
- Roche和Siemens特异性100%,DiaSorin 96.1%至97.0%,EUROIMMUN 86.3%至96.4%。
临床怎么用
- 实验室应了解SARS-CoV-2血清学检测选项的优势与局限性;Roche和Siemens检测适用于低流行区域,联合使用可发挥正交检测优势。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Serologic testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has experienced a changing landscape of available assays coupled with uncertainty surrounding performance characteristics. Studies are needed to directly compare multiple commercially available assays. METHODS: Residual serum samples were identified based on SARS-CoV-2 reverse transcription polymerase chain reaction (RT-PCR) testing, clinical test results, and collection dates. Serum samples were analyzed using assays from four different manufacturers: DiaSorin anti-SARS-CoV-2 S1/S2 IgG, EUROIMMUN anti-SARS-CoV-2 IgG ELISA, Roche Elecsys anti-SARS-CoV-2, and Siemens SARS-CoV-2 Total antibody assays. RESULTS: Samples from SARS-CoV-2 RT-PCR-positive patients became increasingly positive as time from symptom onset increased. For patients with latest sample 14 or more days after symptom onset, sensitivities reached 93.1% to 96.6%, 98.3%, and 96.6% for EUROIMMUN, Roche, and Siemens assays, respectively, which were superior to the DiaSorin assay at 87.7%. The specificity of Roche and Siemens assays was 100% and superior to DiaSorin and EUROIMMUN assays, which ranged from 96.1% to 97.0% and 86.3% to 96.4%, respectively. CONCLUSIONS: Laboratories should be aware of the advantages and limitations of serology testing options for SARS-CoV-2. The specificity and sensitivity achieved by the Roche and Siemens assays would be acceptable for testing in lower-prevalence regions and have the potential of orthogonal testing advantages if used in combination.
引用
- Manthei DM, Whalen JF, Schroeder LF, et al. Differences in Performance Characteristics Among Four High-Throughput Assays for the Detection of Antibodies Against SARS-CoV-2 Using a Common Set of Patient Samples. Am J Clin Pathol. 2021. PMID: 33033840. doi:10.1093/ajcp/aqaa200
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。